MaxCyte Inc reports results for the quarter ended in September 30 - Earnings Summary

MaxCyte

07/11/2024 05:12

* MaxCyte Inc  MXCT.OQ  reported a quarterly adjusted loss
of 11
cents​​ per share for the quarter ended September 30, identical
to the same quarter last year.  The mean expectation of
six analysts for the quarter was for a loss of 12 cents per
share. Wall Street expected results to range from -15 cents
to -11 cents per share.
    * Revenue rose 2% to $8.16 million from a year ago; analysts
expected $7.37 million. 
    * MaxCyte Inc's reported EPS for the quarter was a loss
of 11
cents​.
    * The company reported a quarterly loss of $11.56 million.
    * MaxCyte Inc shares had fallen by 0.3% this quarter and
lost 17.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "strong buy"

Wall Street's median 12-month price target for MaxCyte Inc is
9.50 
This summary was machine generated from LSEG data November 7 at
05:12 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.12          -0.11          Beat
 Jun. 30 2024      -0.13          -0.09          Beat
 Mar. 31 2024      -0.13          -0.09          Beat
 Dec. 31 2023      -0.07          -0.05          Beat